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Background
Growth hormones are produced by the anterior pituitary
gland of vertebrates. Apart from stimulating linear body
growth, it plays an important role in variety of metabolic
and physiological processes. There is almost no informa-
tion on mink growth hormone (mGH), which probably
could be a useful factor in mink fur production, synthesis
in E.coli and future recovery of bioactive protein. It is
known that mGH gene was cloned and sequenced [1,2].
We report the possibility to produce large amounts of
mGH using recombinant DNA technology.
Results
The host strain E. coli BL21(DE3) harbouring the plasmid
pET21a+/mGH was grown in batch fermentation process
at 37°C using nutrient rich medium to produce mGH.
The target protein expression was induced with 0.2 mM or
1 mM of isopropyl-β-D-thiogalactoside at OD600 of 2.0. In
both cases after 3 hours of induction the expression level
was similar and equal to 23% and 27% of the total cellular
protein, respectively. mGH when overexpressed in E. coli
accumulated as inclusion bodies. After cell disruption by
sonication inclusion bodies were purified by washing
with water, then with cleaning solution (2 M urea, 1 M
NaCl, 5 mM EDTA, 1 mM PMSF in 0.1 M Tris-HCl buffer
pH 9.0) and once more with water. The washed inclusion
bodies were found to contain approximately 80% of
mGH. 8 M urea solution was used for its solubilization.
mGH was refolded by dilution protocol in the presence of
glutathione pair. The mGH conformational state was ana-
lyzed by RP-HPLC. Two-step purification process com-
prising of ion-exchange chromatography on Q-Sepharose
and hydrophobic chromatography on Phenyl-Sepharose
was developed. The biological activity of the purified
mGH was assessed in vitro using a mouse myeloid cell
line transfected with the full length ovine GH receptor [3].
Stimulation of cells was assessed using the MTT-formazan
dye assay, that monitors both metabolic and mitogenic
activity. 25–30 mg of highly purified and biologically
active mGH was obtained from 4 g of biomass.
Conclusion
The method presented here allows producing large quan-
tities of mGH and considering initiation of scientific
investigations on mGH availability in fur industry.
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